» Articles » PMID: 20410263

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-react Against 2009 Pandemic H1N1 Influenza Virus

Overview
Journal J Virol
Date 2010 Apr 23
PMID 20410263
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

While few children and young adults have cross-protective antibodies to the pandemic H1N1 2009 (pdmH1N1) virus, the illness remains mild. The biological reasons for these epidemiological observations are unclear. In this study, we demonstrate that the bulk memory cytotoxic T lymphocytes (CTLs) established by seasonal influenza viruses from healthy individuals who have not been exposed to pdmH1N1 can directly lyse pdmH1N1-infected target cells and produce gamma interferon (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha). Using influenza A virus matrix protein 1 (M1(58-66)) epitope-specific CTLs isolated from healthy HLA-A2(+) individuals, we further found that M1(58-66) epitope-specific CTLs efficiently killed both M1(58-66) peptide-pulsed and pdmH1N1-infected target cells ex vivo. These M1(58-66)-specific CTLs showed an effector memory phenotype and expressed CXCR3 and CCR5 chemokine receptors. Of 94 influenza A virus CD8 T-cell epitopes obtained from the Immune Epitope Database (IEDB), 17 epitopes are conserved in pdmH1N1, and more than half of these conserved epitopes are derived from M1 protein. In addition, 65% (11/17) of these epitopes were 100% conserved in seasonal influenza vaccine H1N1 strains during the last 20 years. Importantly, seasonal influenza vaccination could expand the functional M1(58-66) epitope-specific CTLs in 20% (4/20) of HLA-A2(+) individuals. Our results indicated that memory CTLs established by seasonal influenza A viruses or vaccines had cross-reactivity against pdmH1N1. These might explain, at least in part, the unexpected mild pdmH1N1 illness in the community and also might provide some valuable insights for the future design of broadly protective vaccines to prevent influenza, especially pandemic influenza.

Citing Articles

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.

Mu X, Cohen C, Leung D, Rosa Duque J, Cheng S, Chung Y Signal Transduct Target Ther. 2022; 7(1):397.

PMID: 36517469 PMC: 9748396. DOI: 10.1038/s41392-022-01282-7.


A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets.

van de Ven K, Lanfermeijer J, van Dijken H, Muramatsu H, Vilas Boas de Melo C, Lenz S Sci Adv. 2022; 8(50):eadc9937.

PMID: 36516261 PMC: 9750153. DOI: 10.1126/sciadv.adc9937.


Understanding the Role of HLA Class I Molecules in the Immune Response to Influenza Infection and Rational Design of a Peptide-Based Vaccine.

Muraduzzaman A, Illing P, Mifsud N, Purcell A Viruses. 2022; 14(11).

PMID: 36423187 PMC: 9695287. DOI: 10.3390/v14112578.


Homologous peptides derived from influenza A, B and C viruses induce variable CD8 T cell responses with cross-reactive potential.

Nguyen A, Lau H, Sloane H, Jayasinghe D, Mifsud N, Chatzileontiadou D Clin Transl Immunology. 2022; 11(10):e1422.

PMID: 36275878 PMC: 9581725. DOI: 10.1002/cti2.1422.


FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN-γ and Granzyme B ELISpot Assay.

Oftung F, Naess L, Laake I, Stoloff G, Pleguezuelos O Vaccines (Basel). 2022; 10(9).

PMID: 36146606 PMC: 9505334. DOI: 10.3390/vaccines10091528.


References
1.
Djeu J, Jiang K, Wei S . A view to a kill: signals triggering cytotoxicity. Clin Cancer Res. 2002; 8(3):636-40. View

2.
Rimmelzwaan G, Fouchier R, Osterhaus A . Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol. 2007; 18(6):529-36. DOI: 10.1016/j.copbio.2007.11.002. View

3.
Dawood F, Jain S, Finelli L, Shaw M, Lindstrom S, Garten R . Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009; 360(25):2605-15. DOI: 10.1056/NEJMoa0903810. View

4.
Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M . In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009; 460(7258):1021-5. PMC: 2748827. DOI: 10.1038/nature08260. View

5.
Fraser C, Donnelly C, Cauchemez S, Hanage W, Van Kerkhove M, Hollingsworth T . Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009; 324(5934):1557-61. PMC: 3735127. DOI: 10.1126/science.1176062. View